Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
Paul Nyirjesy, Jane R Schwebke, David A Angulo, Itzel A Harriott, Nkechi E Azie, Jack D Sobel, Paul Nyirjesy, Jane R Schwebke, David A Angulo, Itzel A Harriott, Nkechi E Azie, Jack D Sobel
Abstract
Background: Vulvovaginal candidiasis affects approximately 75% of women in their lifetime. Approved treatment options are limited to oral or topical azoles. Ibrexafungerp, a novel, first-in-class oral triterpenoid glucan synthase inhibitor, has demonstrated broad fungicidal Candida activity and a favorable tolerability profile. The primary objective of this dose-finding study was to identify the optimal dose of oral ibrexafungerp in patients with acute vulvovaginal candidiasis.
Methods: Patients with vulvovaginal signs and symptoms score ≥7 were randomized equally to 6 treatments groups: 5 treatment doses of oral ibrexafungerp or oral fluconazole 150 mg. The primary endpoint was the percentage of patients with a clinical cure (complete resolution of vulvovaginal signs and symptoms) at the test-of-cure visit (day 10).
Results: Overall, 186 patients were randomized into the 6 treatment groups. Results, using the modified intent-to-treat population (baseline positive culture), are reported for ibrexafungerp 300 mg twice daily (BID) for 1 day (n = 27), which was the dose selected for phase 3 studies, and fluconazole 150 mg for 1 day (n = 24). At day 10, the clinical cure rates for ibrexafungerp and fluconazole were 51.9% and 58.3%, respectively; at day 25, patients with no signs or symptoms were 70.4% and 50.0%, respectively. During the study ibrexafungerp patients required less antifungal rescue medications compared with fluconazole (3.7% vs 29.2%, respectively). Ibrexafungerp was well tolerated, with the most common treatment-related adverse events being mild gastrointestinal events.
Conclusions: Ibrexafungerp is a well-tolerated novel antifungal with comparable efficacy to fluconazole in the treatment of acute vulvovaginal candidiasis.
Clinical trials registration: NCT03253094.
Keywords: Candida albicans; SCY-078; fluconazole; ibrexafungerp; vulvovaginal candidiasis.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures
References
- Mendling W, Brasch J, Cornely OA, et al. . Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 2015; 58:1–15.
- Workowski KA, Bolan GA; Centers for Disease Control and Prevention. . Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1–137.
- Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans Candida species in vulvovaginitis. J Fungi 2018; 4:121.
- Jeanmonod R, Jeanmonod D.. Vaginal candidiasis. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2020. Available at: . Updated 21 November 2020. Accessed 9 December 2020.
- Committee on Practice Bulletins—Gynecology. Vaginitis in nonpregnant patients: ACOG practice bulletin, Number 215. Obstet Gynecol 2020; 135:e1–17.
- Diflucan [package insert]. New York: Pfizer Inc, 2020.
- Bérard A, Sheehy O, Zhao JP, et al. . Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ 2019; 191:E179–87.
- van Schalkwyk J, Yudin MH; INFECTIOUS DISEASE COMMITTEE. . Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. J Obstet Gynaecol Can 2015; 37:266–74.
- Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 2013; 369:830–9.
- Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012; 120:1407–14.
- Mintz JD, Martens MG. Prevalence of non-albicans Candida infections in women with recurrent vulvovaginal symptomatology. Adv Infect Dis 2013; 3:238–42.
- Hasim S, Coleman JJ. Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents. Future Med Chem 2019; 11:869–83.
- Jiménez-Ortigosa C, Perez WB, Angulo D, Borroto-Esoda K, Perlin DS. De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring Echinocandin resistance. Antimicrob Agents Chemother 2017; 61:e00833–17.
- Azie N, Angulo D, Dehn B, Sobel JD. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis. Expert Opin Investig Drugs 2020; 29:893–900.
- Gintjee TJ, Donnelley MA, Thompson GR III. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi (Basel) 2020; 6:28.
- Larkin EL, Long L, Isham N, et al. . A novel 1,3-beta-D-glucan inhibitor, ibrexafungerp (formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis. Antimicrob Agents Chemother 2019; 63:e02611–18.
- Wring S, Borroto-Esoda K, Solon E, Angulo D. SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14 C]SCY-078 in albino and pigmented rats. Antimicrob Agents Chemother 2019; 63:e02119–18.
- Roman M, Hernandez C, Blanco D, Obrycki G, Helou S, Angulo D. SCY-078 phase 2 study in moderate and severe vulvovaginal candidiasis (VVC) [abstract P1748]. In: 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22–25 April 2017.
- Angulo D, Murphy G, Atiee G, Corr C, Willett M, Wring S. Effect of SCY-078 on the pharmacokinetics of tacrolimus: results from a phase 1 clinical drug-drug interaction trial [abstract P1738]. In: 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22–25 April 2017.
- Angulo D, Murphy G, Atiee G, Corr C, Willett M, Wring S. Effect of SCY-078 on the pharmacokinetics of CYP2C8 substrate (rosiglitazone): results from a phase 1 clinical trial [abstract P1713]. In: 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22–25 April 2017.
- US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Vulvovaginal candidiasis: developing drugs for treatment. Guidance for industry. 2019. Available at: . Accessed 9 December 2020.
- Fan S, Liu X, Liang Y. Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis. Gynecol Obstet Invest 2015; 80:113–8.
- Sekhavat L, Tabatabaii A, Tezerjani FZ. Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. J Infect Public Health 2011; 4:195–9.
- Sobel JD, Kapernick PS, Zervos M, et al. . Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001; 185:363–9.
- Zhou X, Li T, Fan S, et al. . The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. Mycoses 2016; 59:419–28.
Source: PubMed